Pro: Cardiovascular calcifications are clinically relevant

Nephrology Dialysis Transplantation

Volumn 30, Issue 3, 2015, Pages 345-351

  Bover, Jordi ^a   Evenepoel, Pieter ^b   Ureña Torres, Pablo ^c,d   Vervloet, Marc G ^e   Brandenburg, Vincent ^f   Mazzaferro, Sandro ^g   Covic, Adrian ^h   Goldsmith, David ⁱ   Massy, Ziad A ^j,k   Cozzolino, Mario ^l  

^a FUNDACIÓ PUIGVERT   (Spain)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Clinique du Landy   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j HÔPITAL AMBROISE PARÉ   (France)

^k UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

chronic kidney disease; dialysis; hyperphosphataemia; vascular calcification

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SODIUM THIOSULFATE; VITAMIN D DERIVATIVE; VITAMIN K GROUP; WARFARIN; MINERAL;

ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; END STAGE RENAL DISEASE; HIGH RISK PATIENT; HUMAN; HYPERPHOSPHATEMIA; MINERAL AND BONE DISORDER; PERSONALIZED MEDICINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING; SECONDARY HYPERPARATHYROIDISM; UREMIA; VITAMIN K DEFICIENCY; CALCINOSIS; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; METABOLISM; PATHOPHYSIOLOGY;

BONE DISEASES; CALCINOSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; MINERALS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84924418930     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv020     Document Type: Review

References (40)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBDWork Group. Kidney Int Suppl 2009; 76(suppl.113): S1-S130
2. Cozzolino M, Ureña-Torres P, Vervloet MG et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 2014; 29: 1815-1820
3. Raggi P, Chertow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327-1339
4. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-1488
5. Bellasi A, Raggi P. Vascular imaging in chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 382-388
6. Gross P, Six I, Kamel S et al. Vascular toxicity of phosphate in chronic kidney disease. Circ J 2014; 78: 2339-2346
7. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013; 24: 179-189
8. Lu KC, Wu CC, Yen JF et al. Vascular calcification and renal bone disorders. SciWorld J 2014; 2014: 1-20
9. O'Neill WC, Adams AL. Breast arterial calcification in chronic kidney disease: absence of smooth muscle apoptosis and osteogenic transdifferentiation. Kidney Int 2014; 85: 668-676
10. Brandenburg VM, Ketteler M, Rodriguez M. Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps. Kidney Int Suppl 2011; 1: 116-121
11. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010; 122: 2748-2764
12. Matsushita K, Sang Y, Ballew SH et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol 2015; 26: 439-447
13. Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol 2014; 25: 327-332
14. Pelisek J, Assadian A, Sarkar O et al. Carotid plaque composition in chronic kidney disease: a retrospective analysis of patients undergoing carotid endarterectomy. Eur J Vasc Endovasc Surg 2010; 39: 11-16
15. Cozzolino M, Staniforth ME, Liapis H et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-1661
16. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307
17. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
18. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-434
19. Floege J, Raggi P, Block GA et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1916-1923
20. Ureña-Torres PA, Floege J, Hawley CM et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 2013; 28: 146-152
21. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13: 134-141
22. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
23. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431
24. Toussaint ND, Lau KK, Polkinghorne KR et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 2011; 16: 290-298
25. Di Iorio B, Molony D, Bell C et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778
26. Di Iorio B, Bellasi A, Russo D et al. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7: 487-493
27. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277
28. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
29. Lemos MM,Watanabe R, Carvalho AB et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clin Nephrol 2013; 80: 1-8
30. Ivanovski O, Nikolov IG, Joki N et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009; 205: 55-62
31. Chertow GM, Block GA, Correa-Rotter R et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
32. Palmer SC, Nistor I, Craig JC et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10: e1001436
33. Naves-Díaz M, Cabezas-Rodríguez I, Barrio-Vázquez S et al. Low calcidiol levels and risk of progression of aortic calcification. Osteoporos Int 2012; 23: 1177-1182
34. Lau WL, Leaf EM, Hu MC et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82: 1261-1270
35. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
36. Duranton F, Rodriguez-Ortiz ME, Duny Y et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 2013; 37: 239-248
37. Lomashvili KA, Monier-Faugere MC, Wang X et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 2009; 75: 617-625
38. Adirekkiat S, Sumethkul V, Ingsathit A et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1923-1929
39. Goldsmith DJ, Covic A, Fouque D et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 25: 3823-3831
40. Torregrosa JV, Bover J, Cannata Andía J et al. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrologia 2011; 31 (Suppl 1): 3-32